Osteoporosis in the rheumatic disease patient

Nancy E Lane, Q. Rehman

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Rheumatic disease patients often have both systemic and localized inflammatory processes. The result of this inflammation is tissue destruction and this translates into bone loss. Recent studies have highlighted the importance of systemic factors that either directly or indirectly activate receptor activator of nuclear factor-kB ligand (RANKL) dependent osteoclast activation and induce bone loss. In this article we will review the pathogenesis of inflammatory bone loss and explore the possible interventions to prevent it.

Original languageEnglish (US)
Pages (from-to)675-679
Number of pages5
JournalLupus
Volume11
Issue number10
DOIs
StatePublished - 2002
Externally publishedYes

Fingerprint

Rheumatic Diseases
Osteoporosis
Bone and Bones
Osteoclasts
Cytoplasmic and Nuclear Receptors
Ligands
Inflammation

Keywords

  • Bone loss
  • Rheumatology patients

ASJC Scopus subject areas

  • Rheumatology
  • Immunology

Cite this

Osteoporosis in the rheumatic disease patient. / Lane, Nancy E; Rehman, Q.

In: Lupus, Vol. 11, No. 10, 2002, p. 675-679.

Research output: Contribution to journalArticle

Lane, Nancy E ; Rehman, Q. / Osteoporosis in the rheumatic disease patient. In: Lupus. 2002 ; Vol. 11, No. 10. pp. 675-679.
@article{66549af5c30c4d2283cd7258269d319d,
title = "Osteoporosis in the rheumatic disease patient",
abstract = "Rheumatic disease patients often have both systemic and localized inflammatory processes. The result of this inflammation is tissue destruction and this translates into bone loss. Recent studies have highlighted the importance of systemic factors that either directly or indirectly activate receptor activator of nuclear factor-kB ligand (RANKL) dependent osteoclast activation and induce bone loss. In this article we will review the pathogenesis of inflammatory bone loss and explore the possible interventions to prevent it.",
keywords = "Bone loss, Rheumatology patients",
author = "Lane, {Nancy E} and Q. Rehman",
year = "2002",
doi = "10.1191/0961203302lu261oa",
language = "English (US)",
volume = "11",
pages = "675--679",
journal = "Lupus",
issn = "0961-2033",
publisher = "SAGE Publications Ltd",
number = "10",

}

TY - JOUR

T1 - Osteoporosis in the rheumatic disease patient

AU - Lane, Nancy E

AU - Rehman, Q.

PY - 2002

Y1 - 2002

N2 - Rheumatic disease patients often have both systemic and localized inflammatory processes. The result of this inflammation is tissue destruction and this translates into bone loss. Recent studies have highlighted the importance of systemic factors that either directly or indirectly activate receptor activator of nuclear factor-kB ligand (RANKL) dependent osteoclast activation and induce bone loss. In this article we will review the pathogenesis of inflammatory bone loss and explore the possible interventions to prevent it.

AB - Rheumatic disease patients often have both systemic and localized inflammatory processes. The result of this inflammation is tissue destruction and this translates into bone loss. Recent studies have highlighted the importance of systemic factors that either directly or indirectly activate receptor activator of nuclear factor-kB ligand (RANKL) dependent osteoclast activation and induce bone loss. In this article we will review the pathogenesis of inflammatory bone loss and explore the possible interventions to prevent it.

KW - Bone loss

KW - Rheumatology patients

UR - http://www.scopus.com/inward/record.url?scp=0036029872&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036029872&partnerID=8YFLogxK

U2 - 10.1191/0961203302lu261oa

DO - 10.1191/0961203302lu261oa

M3 - Article

VL - 11

SP - 675

EP - 679

JO - Lupus

JF - Lupus

SN - 0961-2033

IS - 10

ER -